UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

[
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
[og_img]
https://www.investing.com/news/press-releases/unity-biotechnology-to-host-virtual-investor-event-to-discuss-24-and-36week-data-from-the-phase-2b-aspire-study-of-ubx1325-in-patients-with-diabetic-macular-edema-dme-on-march-24-2025-93CH-3943431


Investing.com